Private Ocean LLC Sells 225 Shares of Edwards Lifesciences Co. (NYSE:EW)

Private Ocean LLC cut its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 15.8% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,200 shares of the medical research company’s stock after selling 225 shares during the quarter. Private Ocean LLC’s holdings in Edwards Lifesciences were worth $115,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in EW. O Shaughnessy Asset Management LLC lifted its holdings in shares of Edwards Lifesciences by 16.2% during the third quarter. O Shaughnessy Asset Management LLC now owns 23,426 shares of the medical research company’s stock valued at $1,623,000 after acquiring an additional 3,264 shares during the period. Schonfeld Strategic Advisors LLC increased its position in Edwards Lifesciences by 2,233.3% in the third quarter. Schonfeld Strategic Advisors LLC now owns 181,691 shares of the medical research company’s stock worth $12,588,000 after purchasing an additional 173,904 shares during the period. Eventide Asset Management LLC increased its position in Edwards Lifesciences by 91.7% in the third quarter. Eventide Asset Management LLC now owns 9,794 shares of the medical research company’s stock worth $679,000 after purchasing an additional 4,686 shares during the period. Kidder Stephen W increased its position in Edwards Lifesciences by 4.0% in the third quarter. Kidder Stephen W now owns 12,960 shares of the medical research company’s stock worth $898,000 after purchasing an additional 500 shares during the period. Finally, Quadrature Capital Ltd acquired a new stake in Edwards Lifesciences in the third quarter worth about $4,940,000. 79.46% of the stock is owned by institutional investors.

Edwards Lifesciences Stock Performance

Shares of EW stock traded down $0.97 during trading on Friday, reaching $92.37. 11,670,925 shares of the company’s stock were exchanged, compared to its average volume of 2,666,729. The company has a quick ratio of 2.67, a current ratio of 3.75 and a debt-to-equity ratio of 0.08. The stock has a market capitalization of $55.66 billion, a PE ratio of 39.81, a PEG ratio of 3.41 and a beta of 1.11. Edwards Lifesciences Co. has a twelve month low of $60.57 and a twelve month high of $96.12. The firm’s fifty day moving average price is $87.85 and its 200-day moving average price is $85.30.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, April 25th. The medical research company reported $0.66 EPS for the quarter, beating analysts’ consensus estimates of $0.64 by $0.02. Edwards Lifesciences had a return on equity of 22.86% and a net margin of 23.01%. The firm had revenue of $1.60 billion for the quarter, compared to analyst estimates of $1.58 billion. As a group, sell-side analysts anticipate that Edwards Lifesciences Co. will post 2.77 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages recently commented on EW. Piper Sandler lifted their price objective on Edwards Lifesciences from $85.00 to $88.00 and gave the stock a “neutral” rating in a research report on Friday, April 26th. Evercore ISI decreased their target price on Edwards Lifesciences from $92.00 to $89.00 and set an “in-line” rating for the company in a research report on Friday, April 26th. Stifel Nicolaus boosted their target price on Edwards Lifesciences from $83.00 to $85.00 and gave the stock a “hold” rating in a research report on Friday, April 26th. Bank of America upgraded Edwards Lifesciences from a “neutral” rating to a “buy” rating in a research report on Thursday, March 7th. Finally, StockNews.com upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating in a research report on Thursday. One analyst has rated the stock with a sell rating, five have assigned a hold rating and fifteen have assigned a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $95.06.

Insider Transactions at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction on Wednesday, June 12th. The stock was sold at an average price of $87.54, for a total transaction of $437,700.00. Following the sale, the vice president now directly owns 46,936 shares of the company’s stock, valued at approximately $4,108,777.44. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other Edwards Lifesciences news, CEO Bernard J. Zovighian acquired 580 shares of the company’s stock in a transaction that occurred on Monday, May 6th. The stock was acquired at an average cost of $85.74 per share, for a total transaction of $49,729.20. Following the transaction, the chief executive officer now directly owns 3,268 shares in the company, valued at $280,198.32. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction dated Wednesday, June 12th. The shares were sold at an average price of $87.54, for a total value of $437,700.00. Following the sale, the vice president now directly owns 46,936 shares in the company, valued at $4,108,777.44. The disclosure for this sale can be found here. In the last three months, insiders have sold 127,104 shares of company stock valued at $11,267,464. 1.29% of the stock is owned by corporate insiders.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.